Last reviewed 2026-05-31 · How we verify

THDB0206 Injection-Abdomen

Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 1 active Small molecule ✓ Verified May 2026

THDB0206 Injection-Abdomen is a Small molecule drug developed by Tonghua Dongbao Pharmaceutical Co.,Ltd. It is currently in Phase 1 development.

THDB0206 injection is being studied in a clinical trial to evaluate its pharmacokinetics and pharmacodynamics in healthy Chinese subjects. The trial is an open-label, active-controlled, randomized, three-cycle, crossover trial comparing THDB0206 injection to Humalog and BC222insulin lispro injection.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	THDB0206 Injection-Abdomen
Sponsor	Tonghua Dongbao Pharmaceutical Co.,Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

THDB0206 Injection-Abdomen CI brief — competitive landscape report
THDB0206 Injection-Abdomen updates RSS · CI watch RSS
Tonghua Dongbao Pharmaceutical Co.,Ltd portfolio CI

Frequently asked questions about THDB0206 Injection-Abdomen

What is THDB0206 Injection-Abdomen?

THDB0206 Injection-Abdomen is a Small molecule drug developed by Tonghua Dongbao Pharmaceutical Co.,Ltd.

Who makes THDB0206 Injection-Abdomen?

THDB0206 Injection-Abdomen is developed by Tonghua Dongbao Pharmaceutical Co.,Ltd (see full Tonghua Dongbao Pharmaceutical Co.,Ltd pipeline at /company/tonghua-dongbao-pharmaceutical-co-ltd).

What development phase is THDB0206 Injection-Abdomen in?

THDB0206 Injection-Abdomen is in Phase 1.

Manufacturer: Tonghua Dongbao Pharmaceutical Co.,Ltd — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing